City of Hope is treating the first patients in its CAR T cell trial for prostate cancer that has spread to other parts of the body. By using CAR T cell therapy, they aim to target the prostate stem cell antigen (PSCA) in prostate cancer.
The City-of-Hope-sponsored Phase I study looks at the side effects and the optimal dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to other places in the body. PSCA-CAR T cells are immune cells that have been engineered in the laboratory to kill tumor cells. The sponsors accomplish this marvel by using a virus to insert a piece of deoxyribonucleic acid (DNA) into the immune cells that enables them to recognize prostate tumor cells. It is not yet known how well PSCA-CAR T cells works in killing tumor cells in patients with metastatic castration resistant prostate cancer. The study is planned to run through February, 2021.
Those patients with PSCA-positive castration-resistant prostate cancer that has metastasized to other areas in the body, and who meet other requirements, are eligible for the trial, which includes collaboration with the National Cancer Institute, reports the Valdosta Daily Times.
The Challenge: Prostate Cancer
Prostate cancer is the most common cancer in American men next to skin cancer. The American Cancer Society reports that 174,650 men will be diagnosed with prostate cancer and roughly 31,620 will die from the disease in just 1 year.
City of Hope CAR T Production
City of Hope will take the patients’ immune cells called T cells from the blood stream. They have a way to then reprogram them in the laboratory to recognize and attack specific cancer-causing proteins, such as PSCA, and thereafter reintroduced into the bloodstream of the patient. Once in the patient, they execute on their program to seek out and destroy the targeted tumor cells.
Utilizing their own facility known as the Cellular Therapy Production Center, City of Hope manufacturers the CAR T cells utilizing a critical step as reported in the Valdosta Daily Times. The patient T cells are reprogrammed with viruses engineered in another City of Hope GMP facilities called the Center for Biomedicine & Genetics. The two facilities combined with the Chemical GMP Synthesis Facility represent one of the few cancer centers worldwide with the ability to produce GMP cellular, genetic and drug-based therapies for patients.
Call to Action: Do you or a loved on have prostate cancer that might fit the inclusion criteria of City of Hope’s study? They are a clinical research site to be considered—world renowned for developing cancer treatments. Consider scheduling an appointment if you have the ability to do so. TrialSite News concierge services can potentially help.